L-Lysine, often referred to commercially as Lizine, is an essential amino acid. It is applied across domains where additional symptomatic support is needed because it plays a role in managing the fundamental building blocks of protein within the body, making it relevant in contexts involving heightened systemic burden.

This nutritional supplement may promote healthy tissue function, growth, and healing. It is commonly used across conditions presenting with acute episodes and is relevant for easing symptoms related to physical discomfort, symptoms that create noticeable physiological strain, and symptoms of increased neurological or muscular activity. The support helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

This contributes to easing the overall symptom load and may assist with maintaining functional stability in situations where patients experience temporary physiological imbalance.

Quick Fact: Relief for Symptoms that become more disruptive during flare-ups

Regulatory References

1. National Cancer Institute (NCI) Drug Dictionary entry for L-lysine

Eligibility: Who can and cannot use Lizine?

Regulatory documentation defines strict population eligibility criteria for Lizine (Levocetirizine Dihydrochloride).

Classification	Population Group or Condition
ABSOLUTELY CONTRAINDICATED	Patients with known hypersensitivity to levocetirizine, cetirizine, hydroxyzine, or other piperazine derivatives.
	Patients with End-Stage Renal Disease (creatinine clearance less than 10 mL/min).
	Children younger than 6 months of age.
RESTRICTED / CONDITIONAL USE	Patients 12 years of age and older with mild to severe renal impairment (requires dose adjustment).
	Patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia) or epilepsy (use with caution).
AGE ELIGIBILITY	Approved for adults and adolescents 12 years of age and older.
	Approved for children 6 months (oral solution) or 6 years (tablet).
PREGNANCY / LACTATION	Use in pregnancy is generally authorized only if clearly needed (Pregnancy Category B). Use during lactation is not recommended by US regulators.

Lizine is contraindicated in children 6 months to 11 years of age with impaired kidney function. Patients with isolated hepatic impairment are eligible for standard use, as dose adjustments are not typically required.

Interactions with other medicines and products — official regulatory information for Levocetirizine Dihydrochloride

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Central Nervous System (CNS) depressants.
Specific interacting medicines	Alcohol (Ethanol), Ritonavir, Theophylline.
Mechanistic basis of interactions	Pharmacodynamic: Additive impairment of CNS performance. Pharmacokinetic: Altered drug clearance and increased exposure.
Timing-based interaction rules	No mandatory timing separation is required for food.
Population-specific interaction notes	Contraindicated in End-Stage Renal Disease or severe renal impairment.
Interaction-related restrictions	Avoid co-administration with alcohol and other CNS depressants.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Documentation Statement
Interaction severity classification	Avoid co-administration (pharmacodynamic); Contraindicated (renal clearance restriction).
Regulatory basis	FDA and EMA Prescribing Information.
Interaction-context constraints	Contraindication relates directly to the drug's primary renal excretion.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with alcohol and other CNS depressants should be avoided due to the documented pharmacodynamic interaction causing additive impairment of alertness and CNS function.
• The medicine is contraindicated for patients with End-Stage Renal Disease or severe renal impairment, as the drug is predominantly eliminated via the kidneys.
• A pharmacokinetic interaction is documented with Ritonavir, which may lead to an increase in Levocetirizine plasma levels.
• Co-administration with Theophylline (400 mg once daily) resulted in a minor, documented reduction in levocetirizine clearance.
• Taking the medicine with food is noted as having a pharmacokinetic effect of delaying the rate of absorption but does not change the overall amount of drug absorbed.

Connection to the overall interaction profile (2–4 sentences): The regulatory interaction profile is defined by a central pharmacodynamic restriction requiring avoidance of co-use with substances that depress the CNS, such as alcohol. Pharmacokinetically, the structure notes specific clearance effects with agents like Ritonavir and Theophylline. Furthermore, the profile includes a stringent population-based contraindication directly tied to the drug’s substantial dependence on kidney function for elimination.

Lizine (L-lysine) is an essential alpha-amino acid that primarily acts as a substrate for protein biosynthesis and subsequent post-translational modification pathways throughout the body. Following absorption from the small intestine via cationic amino acid transporters (e.g., CAT-1, CAT-2), Lizine is distributed systemically. Intracellularly, it serves as a necessary component for the synthesis of structural proteins, including collagen, where it is hydroxylated by lysyl hydroxylase to form hydroxylysine residues.

Beyond protein synthesis, Lizine is a precursor in the synthesis of carnitine, a molecule required for the transport of long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Lizine can also modulate the activity of the herpes simplex virus (HSV) by acting as an antagonist to the amino acid L-arginine, which is necessary for viral protein synthesis and replication. A resulting shift in the intracellular lysine:arginine ratio inhibits the assembly of viral structural proteins, thereby modulating the infectious cycle.

How to Use Lizine: Administration Guidelines

Lizine (Levocetirizine Dihydrochloride) is an oral medication with specific use instructions to ensure consistent administration. The medicine is available as a film-coated tablet and an oral solution.

---

Standard Dosing and Schedule

Lizine is administered once daily (qDay). The dose is typically taken in the evening.

Population	Standard Dosing Regimen	Maximum Daily Dose
Adults & Adolescents (ge 12 yrs)	5 mg once daily	5 mg/24 hours
Children (6 to 11 yrs)	2.5 mg once daily	2.5 mg/24 hours
Children (6 months to 5 yrs)	1.25 mg (via oral solution) once daily	1.25 mg/24 hours

---

Administration Context and Duration

Lizine can be taken without regard to food, meaning intake is permissible either with or without a meal. For patients using the tablet form, it must be swallowed whole with liquid; the scored tablet allows for accurate administration of the 2.5 mg dose.

For chronic conditions, continuous therapy may be used, with clinical experience supporting administration for periods of at least six months. Conversely, for temporary issues like seasonal symptoms, treatment can be stopped when symptoms subside and restarted if they return.

Population-Specific Adjustments

The dosing interval or dose amount is adjusted for patients with impaired kidney function based on their level of creatinine clearance. Conversely, no dose adjustment is required solely for patients with hepatic impairment.

Research Evidence / Overview of Studies for Lizine

Evidence for Use in Seasonal and Perennial Allergies (Rhinitis)

Lizine (Levocetirizine Dihydrochloride) was studied for use in conditions characterized by fluctuating or episodic manifestations, such as seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Research for these conditions relies heavily on Randomized Controlled Trials (RCTs). These short-term RCTs, often double-blind and placebo-controlled, were the main research applied in studies examining patient-reported experiences. Research measured changes in scores related to physical discomfort, such as sneezing, nasal discharge, itching, and congestion, measured using formal tools like the Total Nasal Symptom Scores (TNSS).

Trial reports compared the measurements captured during the study period to those captured for patients receiving an inactive placebo. The evidence contributes to understanding symptom patterns, particularly focusing on episodes where symptoms become more noticeable. While trials up to six months exist, the majority of the research is restricted to short-term observation periods (2–4 weeks), and long-term data for use beyond six months remain limited.

---

Evidence for Use in Chronic Hives (Idiopathic Urticaria)

For conditions involving periods of heightened symptoms, such as chronic idiopathic urticaria (CIU), Lizine was also studied using controlled clinical trials. The research primarily monitored outcomes related to the physical manifestation of hives (wheals) and the perceived level of itching (pruritus) by monitoring scores like the Urticaria Activity Score (UAS) over short- to intermediate-duration intervals. The findings describe patterns observed in the studies, where measured outcomes for patients receiving Lizine varied compared to those receiving placebo. Studies monitored markers of allergic reactions in the skin during the study period. Data for certain groups, such as patients with CIU that is refractory (non-responsive) to standard doses, remain insufficient.

---

Evidence in Pediatric and Other Specific Populations

Specific trials were conducted in children aged 6 years and older. A distinct line of research was also conducted on the oral solution formulation for a very young pediatric population (infants and young children, 1 to 2 years old). This research examined temporary physiological imbalance related to recurrent cough associated with allergic symptoms. However, the available evidence is limited, and certainty remains low regarding outcomes in the youngest children compared to the volume of evidence available for adults and older children. Comparative evidence is lacking against other agents in the same therapeutic area.

Key Studies & References

1. Efficacy of levocetirizine in infants and young children with recurrent cough associated with allergic symptoms
2. Consensus on the clinical use of levocetirizine in pediatric allergic diseases

Common questions about Lizine (FAQ)

---

Q: What is Lizine and what is it used for?

Lizine is a medicine approved for the treatment of acute herpes labialis (cold sores). According to the official product information, it is designed to manage and reduce the severity of these oral herpes flare-ups.

---

Q: Does Lizine work for other types of herpes or infections?

Regulatory documents state that Lizine is specifically indicated only for the treatment of acute herpes labialis (cold sores). Its use for other types of herpes infections or other conditions is not covered by the official approved indications.

---

Q: Can Lizine be used by children?

Official product information indicates that Lizine is not recommended for use in children and adolescents under 12 years of age. Use in patients younger than 12 has not been established in clinical studies. Questions regarding use in a child should be discussed with a healthcare professional.

---

Q: Is Lizine safe for pregnant women or those who are breastfeeding?

According to the official product information, use during pregnancy and lactation is not recommended. This is a standard precautionary measure. The decision to use this medicine during pregnancy or breastfeeding should be made in consultation with a healthcare professional.

---

Q: What should I do if I forget to use a dose of Lizine?

The official instructions indicate that if a dose is missed, it should be applied when remembered, and then treatment should continue as scheduled. Product labeling also states that a double application should not be used to compensate for a missed dose. Detailed instructions are provided in the 'How to use Lizine' section.

---

Q: How soon after applying Lizine should I expect to see improvement?

Studies and official information indicate that Lizine is intended to reduce the healing time of the cold sore. While individual results vary, the medicine works to interfere with the virus's replication. Clinical studies suggest that adhering to the prescribed regimen is necessary to achieve the treatment's intended benefits.

How to Store and Dispose of Lizine

Official labeling requires Lizine (Levocetirizine Dihydrochloride) to be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C.

---

Storage Requirements

The medication must remain safety sealed in its original carton or container, and should not be used if the protective seal is missing or torn. It is a mandatory requirement that Lizine be kept out of reach of children.

Disposal

Disposal of any unused or expired product must be carried out in accordance with local regulations for pharmaceutical waste, which often involves community take-back programs.